MX2019002429A - Tratamiento de la demencia. - Google Patents

Tratamiento de la demencia.

Info

Publication number
MX2019002429A
MX2019002429A MX2019002429A MX2019002429A MX2019002429A MX 2019002429 A MX2019002429 A MX 2019002429A MX 2019002429 A MX2019002429 A MX 2019002429A MX 2019002429 A MX2019002429 A MX 2019002429A MX 2019002429 A MX2019002429 A MX 2019002429A
Authority
MX
Mexico
Prior art keywords
compound
treatment
dementia
methylthioninium
memantine
Prior art date
Application number
MX2019002429A
Other languages
English (en)
Inventor
Mervyn David Storey John
Michel Wischik Claude
Olaf Schelter Björn
Jude Wischik Damon
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2019002429A publication Critical patent/MX2019002429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Valve Device For Special Equipments (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a tratamientos mejorados para la demencia frontotemporal basada en el uso de un compuesto de metiltioninio en combinación con un compuesto que modifica directamente la neurotransmisión sináptica en el cerebro, como un tratamiento de la enfermedad de Alzheimer sintomático (por ejemplo, acetilcolinesterasa y/o memantina).
MX2019002429A 2016-09-01 2017-08-25 Tratamiento de la demencia. MX2019002429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614834.8A GB201614834D0 (en) 2016-09-01 2016-09-01 Treatment of dementia
PCT/EP2017/071437 WO2018041739A1 (en) 2016-09-01 2017-08-25 Treatment of dementia

Publications (1)

Publication Number Publication Date
MX2019002429A true MX2019002429A (es) 2019-07-08

Family

ID=57139937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002429A MX2019002429A (es) 2016-09-01 2017-08-25 Tratamiento de la demencia.

Country Status (18)

Country Link
US (1) US10842796B2 (es)
EP (1) EP3506904B1 (es)
JP (1) JP7066679B2 (es)
KR (1) KR102559354B1 (es)
CN (1) CN109890391B (es)
AU (1) AU2017318333B2 (es)
CA (1) CA3034625A1 (es)
DK (1) DK3506904T3 (es)
ES (1) ES2847929T3 (es)
GB (1) GB201614834D0 (es)
HR (1) HRP20210162T1 (es)
MX (1) MX2019002429A (es)
MY (1) MY187564A (es)
PL (1) PL3506904T3 (es)
PT (1) PT3506904T (es)
SG (1) SG11201901125TA (es)
SI (1) SI3506904T1 (es)
WO (1) WO2018041739A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
CA3106152A1 (en) * 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
US20210193322A1 (en) 2018-09-05 2021-06-24 Genting Taurx Diagnostic Centre Sdn Bhd Network methods for neurodegenerative diseases
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4342451A1 (en) * 2022-09-22 2024-03-27 Galenicum Health SLU Pharmaceutical compositions and manufacturing methods thereof
US20240115579A1 (en) * 2022-09-22 2024-04-11 Galenicum Health S.L.U. Pharmaceutical compositions and manufacturing methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
JP2005528431A (ja) * 2002-05-31 2005-09-22 ハー・ルンドベック・アクチエゼルスカベット アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物
CA2579169C (en) 2004-09-23 2018-03-06 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
CA2645919C (en) 2006-03-29 2016-05-31 Wista Laboratories Ltd. Thioninium compounds and their use
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
DK2167095T3 (da) 2007-06-19 2019-07-29 Wista Lab Ltd Phenothiazin-forbindelser til behandling af let kognitiv svækkelse
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
WO2011036561A2 (en) 2009-09-24 2011-03-31 Wis Ta Laboratories Ltd. Process
AU2010299571B2 (en) 2009-09-24 2014-07-31 Wista Laboratories Ltd. Crystalline methylthionium chloride (methylene blue) hydrates
SI2673266T1 (sl) * 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
CN102936244B (zh) * 2012-12-04 2015-02-04 合肥工业大学 一种他克林-吩噻嗪异二联体类化合物及其制备方法

Also Published As

Publication number Publication date
EP3506904B1 (en) 2020-12-09
WO2018041739A1 (en) 2018-03-08
KR20190045273A (ko) 2019-05-02
CN109890391A (zh) 2019-06-14
SG11201901125TA (en) 2019-03-28
JP7066679B2 (ja) 2022-05-13
GB201614834D0 (en) 2016-10-19
AU2017318333B2 (en) 2023-05-11
PL3506904T3 (pl) 2021-07-26
EP3506904A1 (en) 2019-07-10
US20190192530A1 (en) 2019-06-27
DK3506904T3 (da) 2021-01-04
AU2017318333A1 (en) 2019-04-18
CN109890391B (zh) 2023-01-31
MY187564A (en) 2021-09-30
JP2019526571A (ja) 2019-09-19
ES2847929T3 (es) 2021-08-04
SI3506904T1 (sl) 2021-03-31
KR102559354B1 (ko) 2023-07-26
PT3506904T (pt) 2021-02-02
CA3034625A1 (en) 2018-03-08
US10842796B2 (en) 2020-11-24
HRP20210162T1 (hr) 2021-03-19

Similar Documents

Publication Publication Date Title
MX2019002429A (es) Tratamiento de la demencia.
EP3140403A4 (en) Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
IL263433A (en) Methods for treating Alzheimer's disease
PH12019500196A1 (en) Compounds and compositions and uses thereof
WO2016097315A3 (en) Blood brain barrier transport molecules and uses thereof
EP3698649A4 (en) MEANS TO PREVENT OR RELIEVE ALZHEIMER'S MORBUS
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MA48939B1 (fr) Compositions comprenant des souches bactériennes
WO2015109318A3 (en) Therapeutic methods
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2015008520A (es) 4-hidroxi-2-metil-5(propan-2-ilideno)ciclohex-3-enocarbaldehido para la prevencion y tratamiento de una enfermedad cognitiva, neurodegenerativa o neuronal.
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EP3429569A4 (en) METHODS FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY FARNESYLATION DE PARIS
MX2017006692A (es) Trastornos neurodegenerativos.
WO2015165980A3 (en) Treatment and prevention of alzheimer's disease (ad)
HK1250658A1 (zh) 用於治療阿爾茨海默病的神經元鈣池操縱的鈣進入途徑的活化
EP3589272A4 (en) METHODS FOR PREVENTING PROPHYLAXIS, SLOWING EVOLUTION OR TREATING ALZHEIMER'S DISEASE
SI3413870T1 (sl) Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
PH12021550213A1 (en) Methods for treating neurodegenerative disorders
EP3528815C0 (fr) 2,6-diaminopurine pour son utilisation dans le traitement ou la prevention des maladies dues a une mutation non-sens
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui